Clinical and economic outcomes of adding [18F]FES PET/CT in estrogen receptor status identification in metastatic and recurrent breast cancer in the US.

Autor: Regina Munter-Young, Adolfo Fuentes-Alburo, Nicholas DiGregorio, Kurt Neeser, Dmitry Gultyaev

Publikováno v: PLoS ONE, Vol 19, Iss 5, p e0302486 (2024)

Background and objectivesCorrect identification of estrogen receptor (ER) status in breast cancer (BC) is crucial to optimize treatment; however, standard of care, involving biopsy and immunohistochemistry (IHC), and other diagnostic tools such as 2-

Externí odkaz: https://doaj.org/article/ffe78734fd1a4b42a6f1d207a4fd13f3

A comprehensive analysis of clinical, quality of life, and cost-effectiveness outcomes of key treatment options for benign prostatic hyperplasia

Autor: Bilal Chughtai, Sirikan Rojanasarot, Kurt Neeser, Dmitry Gultyaev, Shuai Fu, Samir K. Bhattacharyya, Ahmad M. El-Arabi, Ben J. Cutone, Kevin T. McVary

Publikováno v: PLoS ONE, Vol 17, Iss 4 (2022)

Treatment options for men with moderate-to-severe lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) have variable efficacy, safety, and retreatment profiles, contributing to variations in patient quality of life and health

Externí odkaz: https://doaj.org/article/0a37290c734741a79f88c6dbed82b69f

Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81-8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting

Autor: Rong Chen, Dmitry Gultyaev, Johanna Lister, Rong Han, Nan Hu, Jean Malacan, Alexander Solms, Parth Vashi, Jamie O’Hara, Shanlian Hu

Publikováno v: BMC medical research methodology. 22(1)

Background Long-term prophylactic therapy is considered the standard of care for hemophilia A patients. This study models the long-term clinical and cost outcomes of two factor VIII (FVIII) products using a pharmacokinetic (PK) simulation model in a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3371684d26560cdd728285650ef954cc
https://pubmed.ncbi.nlm.nih.gov/35931967

OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales

Autor: Dmitry Gultyaev, Johanna Lister, Clara Loveman, Marcus J. Drake, Nick Freemantle, Kristin Khalaf, S Stanisic

Publikováno v: Freemantle, N, Khalaf, K, Loveman, C, Stanisic, S, Gultyaev, D, Lister, J & Drake, M 2016, ' OnabotulinumtoxinA in the treatment of overactive bladder : a cost-effectiveness analysis versus best supportive care in England and Wales ', European Journal of Health Economics, vol. 17, no. 7, pp. 911-921 . https://doi.org/10.1007/s10198-015-0737-2

The cost-effectiveness of onabotulinumtoxinA (BOTOX(®)) 100 U + best supportive care (BSC) was compared with BSC alone in the management of idiopathic overactive bladder in adult patients who are not adequately managed with anticholinergics. BSC inc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::771e8133e6c91d3e87ad681e49a46633
https://doi.org/10.1007/s10198-015-0737-2

Prediction of acute and chronic complications by a new computer simulation model for type 1 and type 2 diabetes: the Diabetes Mel l it us Model (DMM)

Autor: Andrew D. Morris, Rito Bergemann, Stefanie Maxion-Bergemann, Sean F Dinneen, Dmitry Gultyaev, Samy Suissa, Hans Hauner, Elvira Müller

Publikováno v: Journal of Medical Economics. 9:83-99

SummaryAn epidemiological simulation model for patients with type 1 and type 2 diabetes (the Diabetes Mellitus Model (DMM)) was developed based on published clinical and observational data and expert estimations, for prediction of short- and long-ter

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3ad13c97d789c1c8082c9ca53a03e05a
https://doi.org/10.3111/200609083099